https://www.pharmaradar360.com/article/drug-label-update-loperamide-hydrochloride-34f527e2a863fad9Pharma Surgeen2026-06-30T00:00:00.000ZDrug label update: Loperamide Hydrochloridehttps://www.pharmaradar360.com/article/drug-label-update-nystatin-c4a3e9d3e9bda5e6Pharma Surgeen2026-06-30T00:00:00.000ZDrug label update: NYSTATINhttps://www.pharmaradar360.com/article/why-natera-s-prospera-could-reshape-how-eledon-measures-kidney-transplant-injury-80cc74f8855cc610Pharma Surgeen2026-06-29T16:23:32.000ZWhy Natera’s Prospera could reshape how Eledon measures kidney transplant injury in Phase 3.https://www.pharmaradar360.com/article/cover-of-vaccination-evaluated-rapidly-cover-programme-2025-to-2026-quarterly-da-ec5c68eb5b9089f9Pharma Surgeen2026-06-29T15:56:09.000ZCover of vaccination evaluated rapidly (COVER) programme 2025 to 2026: quarterly datahttps://www.pharmaradar360.com/article/health-protection-report-current-issue-and-latest-surveillance-reports-5ed3a5edbdab3b1aPharma Surgeen2026-06-29T15:53:41.000ZHealth Protection Report: current issue and latest surveillance reportshttps://www.pharmaradar360.com/article/vaccine-uptake-guidance-and-the-latest-coverage-data-35c22e77947ea440Pharma Surgeen2026-06-29T15:53:17.000ZVaccine uptake guidance and the latest coverage datahttps://www.pharmaradar360.com/article/efpia-urges-innovation-friendly-approach-in-submission-on-eu-biotech-act-ii-b5908d054f3bea74Pharma Surgeen2026-06-29T15:22:30.000ZEFPIA urges innovation-friendly approach in submission on EU Biotech Act IIhttps://www.pharmaradar360.com/article/guidance-borderline-products-medical-devices-and-other-products-3e47418eda21a643Pharma Surgeen2026-06-29T15:20:59.000ZGuidance: Borderline products: medical devices and other productshttps://www.pharmaradar360.com/article/biotech-bigwigs-abbv-jnj-biib-lly-hit-new-52-week-highs-0a8f70fe08b3e2e0Pharma Surgeen2026-06-29T15:10:00.000ZBiotech Bigwigs ABBV, JNJ, BIIB & LLY Hit New 52-Week Highshttps://www.pharmaradar360.com/article/what-s-standing-between-reshoring-ambitions-and-reality-ad69be0976d691e1Pharma Surgeen2026-06-29T15:08:48.000ZWhat's Standing Between Reshoring Ambitions and Reality?https://www.pharmaradar360.com/article/shanghai-fudan-zhangjiang-bio-pharmaceutical-co-ltd-class-h-2def001393d0942dPharma Surgeen2026-06-29T15:08:30.000ZShanghai Fudan Zhangjiang Bio Pharmaceutical Co. Ltd. Class Hhttps://www.pharmaradar360.com/article/fda-rejects-sobi-s-gout-drug-over-manufacturing-issues-sparing-amgen-blockbuster-86ea236e23717550Pharma Surgeen2026-06-29T15:04:30.000ZFDA rejects Sobi’s gout drug over manufacturing issues, sparing Amgen blockbusterhttps://www.pharmaradar360.com/article/tnvitamins-moringa-supplement-recall-issued-over-salmonella-risk-fda-says-0649d285c346bb7aPharma Surgeen2026-06-29T14:50:29.000ZTNVitamins moringa supplement recall issued over salmonella risk, FDA sayshttps://www.pharmaradar360.com/article/syre-and-spyre-ride-new-ibd-trends-in-biotech-drug-design-e12fb7047c38de30Pharma Surgeen2026-06-29T14:37:30.000ZSYRE and Spyre Ride New IBD Trends in Biotech Drug Designhttps://www.pharmaradar360.com/article/alpha-1-antitrypsin-gene-editing-startup-raises-230-million-serapha-bio-aatd-deb-c1ddae6fe10c7014Pharma Surgeen2026-06-29T14:37:30.000ZAlpha-1 Antitrypsin Gene Editing Startup Raises $230 Million: Serapha Bio AATD Debuthttps://www.pharmaradar360.com/article/biodexa-pharmaceuticals-bdrx-expands-phase-3-clinical-trial-to-canada-9f9d4d710667f7f6Pharma Surgeen2026-06-29T14:34:01.000ZBiodexa Pharmaceuticals (BDRX) Expands Phase 3 Clinical Trial to Canadahttps://www.pharmaradar360.com/article/biotech-spac-deal-gets-it-to-nasdaq-astrazeneca-phase-3-win-in-children-s-bone-d-8042a7ad4bfd70f0Pharma Surgeen2026-06-29T14:34:00.000ZBiotech SPAC deal gets it to Nasdaq; AstraZeneca Phase 3 win in children's bone diseasehttps://www.pharmaradar360.com/article/larimar-stock-slides-15-despite-fda-backing-rolling-submission-for-rare-disease-ff1e82132cd422e0Pharma Surgeen2026-06-29T14:15:41.000ZLarimar Stock Slides 15% Despite FDA Backing Rolling Submission For Rare Disease Drughttps://www.pharmaradar360.com/article/dcoy-stock-explodes-higher-as-volatile-biotech-trading-heats-up-e67b19e3709f5d09Pharma Surgeen2026-06-29T14:03:00.000ZDCOY Stock Explodes Higher As Volatile Biotech Trading Heats Uphttps://www.pharmaradar360.com/article/evommune-s-phase-2b-trial-flops-ending-challenge-to-novartis-in-hives-c54492e591d5e90cPharma Surgeen2026-06-29T14:00:00.000ZEvommune’s phase 2b trial flops, ending challenge to Novartis in hiveshttps://www.pharmaradar360.com/article/talawar-tx-launches-as-publicly-traded-biotech-d51a011b0086d422Pharma Surgeen2026-06-29T13:58:37.000ZTalawar Tx launches as publicly traded biotechhttps://www.pharmaradar360.com/article/talawar-bets-bispecific-approach-can-shake-up-eczema-market-51bfde1fb223cd90Pharma Surgeen2026-06-29T13:54:31.000ZTalawar bets bispecific approach can shake up eczema markethttps://www.pharmaradar360.com/article/pro-life-states-get-victory-against-mail-order-abortions-in-appeals-court-ruling-82b2073b504322b5Pharma Surgeen2026-06-29T13:51:00.000ZPro-Life States Get Victory Against Mail-Order Abortions in Appeals Court Rulinghttps://www.pharmaradar360.com/article/national-formulary-will-make-shortages-worse-suggests-npa-chair-80376c8ce2a6f738Pharma Surgeen2026-06-29T13:40:50.000ZNational formulary will make shortages worse, suggests NPA chairhttps://www.pharmaradar360.com/article/genentech-adjacent-japanese-drugmaker-sets-up-peninsula-office-looks-for-deals-34e509706746812ePharma Surgeen2026-06-29T13:34:00.000ZGenentech-adjacent Japanese drugmaker sets up Peninsula office, looks for dealshttps://www.pharmaradar360.com/article/lycia-raises-75m-as-degrader-pipeline-moves-toward-patient-data-1357a02f49fb6712Pharma Surgeen2026-06-29T13:32:07.000ZLycia raises $75m as degrader pipeline moves toward patient datahttps://www.pharmaradar360.com/article/united-therapeutics-nabs-fda-approval-for-donor-lung-assessment-device-7549999e6066271cPharma Surgeen2026-06-29T13:27:06.000ZUnited Therapeutics nabs FDA approval for donor-lung assessment devicehttps://www.pharmaradar360.com/article/french-biotech-company-ipsen-to-buy-kartos-therapeutics-for-450-million-d604fc61f0bdb53ePharma Surgeen2026-06-29T13:24:45.000ZFrench biotech company Ipsen to buy Kartos Therapeutics for $450 millionhttps://www.pharmaradar360.com/article/nashik-fda-warns-food-businesses-of-strict-action-over-safety-violations-says-no-00ff747e0931768fPharma Surgeen2026-06-29T13:21:28.000ZNashik: FDA Warns Food Businesses Of Strict Action Over Safety Violations; Says No Compromise On Public Healthhttps://www.pharmaradar360.com/article/4d-molecular-fdmt-completes-enrollment-for-phase-3-clinical-tr-f46c9c69b827c846Pharma Surgeen2026-06-29T13:09:24.000Z4D Molecular (FDMT) Completes Enrollment for Phase 3 Clinical Trhttps://www.pharmaradar360.com/article/biotech-pre-market-pulse-upc-dcoy-juns-post-sharp-moves-65bf894055c16d0dPharma Surgeen2026-06-29T13:06:00.000ZBiotech Pre-Market Pulse: UPC, DCOY, JUNS Post Sharp Moveshttps://www.pharmaradar360.com/article/fda-approves-covid-19-antiviral-xocova-as-pep-but-will-it-be-accessible-bec5d835b47cdd8ePharma Surgeen2026-06-29T13:05:47.000ZFDA Approves COVID-19 Antiviral Xocova as PEP. But Will It Be Accessible?https://www.pharmaradar360.com/article/the-biotech-winter-finally-thaws-e8d08d0ed239b278Pharma Surgeen2026-06-29T13:02:42.000ZThe Biotech Winter Finally Thawshttps://www.pharmaradar360.com/article/replimune-gets-fda-review-for-melanoma-drug-after-prior-setbacks-48400ba9ef61b731Pharma Surgeen2026-06-29T12:58:22.000ZReplimune gets FDA review for melanoma drug after prior setbackshttps://www.pharmaradar360.com/article/krystal-biotech-krys-soars-3-4-is-further-upside-left-in-the-stock-3fa085195064a416Pharma Surgeen2026-06-29T12:49:00.000ZKrystal Biotech (KRYS) Soars 3.4%: Is Further Upside Left in the Stock?https://www.pharmaradar360.com/article/first-patients-treated-via-fda-cleared-transcranial-magnetic-stimulation-plus-fd-30cf6559ace66032Pharma Surgeen2026-06-29T12:46:16.000ZFirst Patients Treated via FDA-Cleared Transcranial Magnetic Stimulation, Plus FDA Grant on D-Cycloserine-Based Drug for Depression: NRx Pharmaceuticals, Inc. (Nasdaq: NRXP)https://www.pharmaradar360.com/article/helus-pharma-reports-phase-3-trial-progress-closes-50m-offering-by-investing-com-860e733cb718de8dPharma Surgeen2026-06-29T12:37:21.000ZHelus Pharma reports Phase 3 trial progress, closes $50M offering By Investing.comhttps://www.pharmaradar360.com/article/us-fda-has-granted-a-rare-pediatric-disease-drug-designation-for-nv-387-as-a-tre-3ce828faac2595ccPharma Surgeen2026-06-29T12:35:03.000ZUS FDA Has Granted A "Rare Pediatric Disease Drug" Designation for NV-387 As A Treatment for Measles - Enables Priority Review Voucherhttps://www.pharmaradar360.com/article/biodexa-s-fap-trial-expands-into-canada-as-enrolment-hits-73-c76fbefbb02b212aPharma Surgeen2026-06-29T12:30:00.000ZBiodexa's FAP trial expands into Canada as enrolment hits 73https://www.pharmaradar360.com/article/fda-rare-pediatric-disease-designation-could-speed-a-measles-drug-review-5679299767b44a65Pharma Surgeen2026-06-29T12:30:00.000ZFDA rare pediatric disease designation could speed a measles drug reviewhttps://www.pharmaradar360.com/article/vivosim-presents-data-showing-superiority-to-competition-in-nam-liver-tox-predic-f3935a82e2f52d58Pharma Surgeen2026-06-29T12:26:01.000ZVivoSim Presents Data Showing Superiority to Competition in NAM Liver Tox Prediction at European Toxicology Meetinghttps://www.pharmaradar360.com/article/eli-lilly-lly-stock-hits-record-high-after-european-drug-approval-and-medicare-e-01f3f0d4caf51aa5Pharma Surgeen2026-06-29T12:25:14.000ZEli Lilly (LLY) Stock Hits Record High After European Drug Approval and Medicare Expansionhttps://www.pharmaradar360.com/article/thailand-and-u-s-strengthen-cooperation-on-produce-pesticide-testing-9561a7e4089ad6b6Pharma Surgeen2026-06-29T12:19:45.000ZThailand and U.S. strengthen cooperation on produce pesticide testinghttps://www.pharmaradar360.com/article/zhejiang-huahai-pharmaceutical-to-sell-off-financial-assets-fb397a039bc99f7ePharma Surgeen2026-06-29T12:18:51.000ZZhejiang Huahai Pharmaceutical to Sell Off Financial Assetshttps://www.pharmaradar360.com/article/4dmt-completes-enrollment-for-4front-2-global-phase-3-clinical-trial-of-4d-150-i-eaaac117d2919cd7Pharma Surgeen2026-06-29T12:05:20.000Z4DMT Completes Enrollment for 4FRONT-2 Global Phase 3 Clinical Trial of 4D-150 in Wet AMDhttps://www.pharmaradar360.com/article/tulipe-en-2025-16-de-produits-de-sante-expedies-pour-renforcer-l-acces-aux-soins-9cfb3754765ec187Pharma Surgeen2026-06-29T12:01:07.000ZTulipe en 2025 : +16 % de produits de santé expédiés pour renforcer l’accès aux soinshttps://www.pharmaradar360.com/article/4dmt-finishes-phase-3-enrollment-for-wet-amd-gene-therapy-trial-8c97d47379696fedPharma Surgeen2026-06-29T12:00:00.000Z4DMT finishes Phase 3 enrollment for wet AMD gene therapy trialhttps://www.pharmaradar360.com/article/uk-based-scancell-bids-to-buy-nasdaq-listed-neuphoria-to-increase-profile-with-u-232806e792852793Pharma Surgeen2026-06-29T11:55:38.000ZUK-based Scancell bids to buy Nasdaq-listed Neuphoria to ‘increase profile’ with US investorshttps://www.pharmaradar360.com/article/viatris-vtrs-reports-positive-phase-3-trial-results-for-vr-205-3fcac9f883274799Pharma Surgeen2026-06-29T11:50:47.000ZViatris (VTRS) Reports Positive Phase 3 Trial Results for VR-205https://www.pharmaradar360.com/article/helus-pharma-reports-recent-business-highlights-and-fiscal-year-2026-financial-r-59778531fbef7a54Pharma Surgeen2026-06-29T11:40:00.000ZHelus Pharma Reports Recent Business Highlights and Fiscal Year 2026 Financial Resultshttps://www.pharmaradar360.com/article/pharmtech-explained-human-accountability-with-ai-in-gmp-519d10994f88f655Pharma Surgeen2026-06-29T11:39:37.000ZPharmTech Explained: Human Accountability with AI in GMPhttps://www.pharmaradar360.com/article/biohaven-s-bhv-1300-targets-the-root-cause-of-graves-disease-in-phase-3-e1ae3e2f18231f48Pharma Surgeen2026-06-29T11:30:00.000ZBiohaven's BHV-1300 targets the root cause of Graves' disease in Phase 3https://www.pharmaradar360.com/article/enterprise-value-to-revenue-forward-of-burning-rock-biotech-ltd-sponsored-adr-du-50e9319dd80683c9Pharma Surgeen2026-06-29T11:28:05.000ZEnterprise value to revenue forward of Burning Rock Biotech Ltd. Sponsored ADR – DUS:6BU0https://www.pharmaradar360.com/article/dianthus-launches-phase-3-trial-for-myasthenia-gravis-treatment-by-investing-com-e46d07b56bcd00e4Pharma Surgeen2026-06-29T11:19:02.000ZDianthus launches phase 3 trial for myasthenia gravis treatment By Investing.comhttps://www.pharmaradar360.com/article/anivive-wins-full-u-s-fda-approval-for-laverdia-first-at-home-oral-treatment-for-3a67f7e2194684ccPharma Surgeen2026-06-29T11:18:43.000ZAnivive Wins Full U.S. FDA Approval for Laverdia, First At-Home Oral Treatment for Canine Lymphomahttps://www.pharmaradar360.com/article/zymeworks-to-acquire-troubled-biotech-theravance-in-929m-deal-6177903a8069bc31Pharma Surgeen2026-06-29T11:13:00.000ZZymeworks to acquire troubled biotech Theravance in $929M dealhttps://www.pharmaradar360.com/article/dianthus-therapeutics-announces-initiation-of-phase-3-emerge-trial-of-clasepruba-a2313cd11db1a046Pharma Surgeen2026-06-29T11:03:46.000ZDianthus Therapeutics Announces Initiation of Phase 3 Emerge Trial of Claseprubart in Generalized Myasthenia Gravishttps://www.pharmaradar360.com/article/reports-of-cases-of-tb-to-uk-enhanced-tuberculosis-surveillance-systems-2000-to-7bbe0add77b9e3d5Pharma Surgeen2026-06-29T11:03:43.000ZReports of cases of TB to UK enhanced tuberculosis surveillance systems 2000 to 2025https://www.pharmaradar360.com/article/relmada-therapeutics-joins-russell-2000-and-russell-3000-indexes-76a3fde067523072Pharma Surgeen2026-06-29T11:00:00.000ZRelmada Therapeutics Joins Russell 2000® and Russell 3000® Indexeshttps://www.pharmaradar360.com/article/dianthus-launches-phase-3-study-of-claseprubart-in-rare-muscle-disease-c1cf30d5729c8a9fPharma Surgeen2026-06-29T11:00:00.000ZDianthus launches Phase 3 study of claseprubart in rare muscle diseasehttps://www.pharmaradar360.com/article/there-s-room-for-multiple-winners-talawar-heads-to-nasdaq-via-spac-deal-to-bankr-776d882fb77c95bdPharma Surgeen2026-06-29T11:00:00.000Z'There's room for multiple winners': Talawar heads to Nasdaq via SPAC deal to bankroll eczema assethttps://www.pharmaradar360.com/article/artivion-s-amds-gets-fda-approval-for-deadly-aortic-tears-638efc8e60572ad1Pharma Surgeen2026-06-29T11:00:00.000ZArtivion’s AMDS gets FDA approval for deadly aortic tearshttps://www.pharmaradar360.com/article/biogen-trims-apellis-pipeline-and-r-d-team-after-5-6bn-takeover-707583c43dca7834Pharma Surgeen2026-06-29T10:59:10.000ZBiogen trims Apellis pipeline and R&D team after $5.6bn takeoverhttps://www.pharmaradar360.com/article/viatris-kidney-drug-vr-205-cut-protein-in-urine-33-75-in-japan-f350fde4db904741Pharma Surgeen2026-06-29T10:59:00.000ZViatris kidney drug VR-205 cut protein in urine 33.75% in Japanhttps://www.pharmaradar360.com/article/merck-announces-new-agreement-with-adap-crisis-task-force-to-improve-access-and-e81dca8917a0fe29Pharma Surgeen2026-06-29T10:45:00.000ZMerck Announces New Agreement with ADAP Crisis Task Force to Improve Access and Care for People Living with HIVhttps://www.pharmaradar360.com/article/ultragenyx-pharmaceutical-inc-nasdaqgs-rare-added-to-russell-2000-growth-benchma-f8932af55bfd32e2Pharma Surgeen2026-06-29T10:41:59.000ZUltragenyx Pharmaceutical Inc.(NasdaqGS:RARE) added to Russell 2000 Growth Benchmarkhttps://www.pharmaradar360.com/article/aspen-api-was-pleased-to-participate-in-tides-us-2026-in-boston-in-may-8bbea61bb78de835Pharma Surgeen2026-06-29T10:36:25.000ZAspen API was pleased to participate in TIDES US 2026 in Boston in Mayhttps://www.pharmaradar360.com/article/sun-pharmaceutical-industries-rises-monday-outperforms-market-4604deb010c5990bPharma Surgeen2026-06-29T10:32:00.000ZSun Pharmaceutical Industries rises Monday, outperforms markethttps://www.pharmaradar360.com/article/larimar-says-fda-can-review-nomlabofusp-for-accelerated-approval-d145ee221aa98021Pharma Surgeen2026-06-29T10:30:00.000ZLarimar says FDA can review nomlabofusp for accelerated approvalhttps://www.pharmaradar360.com/article/yelin-lapidot-holdings-management-ltd-decreases-position-in-teva-pharmaceutical-8a47eb4270e16ee9Pharma Surgeen2026-06-29T10:29:44.000ZYelin Lapidot Holdings Management Ltd. Decreases Position in Teva Pharmaceutical Industries Ltd. $TEVAhttps://www.pharmaradar360.com/article/natera-partners-with-aveta-for-phase-3-head-and-neck-cancer-trial-518d8183a0ff70caPharma Surgeen2026-06-29T10:27:32.000ZNatera partners with Aveta for phase 3 head and neck cancer trialhttps://www.pharmaradar360.com/article/are-you-running-clinical-trials-you-can-now-activate-e-mail-notifications-in-cti-12499280f8872d30Pharma Surgeen2026-06-29T10:27:00.000ZAre you running clinical trials? You can now activate e-mail notifications in CTIShttps://www.pharmaradar360.com/article/natera-and-aveta-biomics-announce-strategic-partnership-supporting-global-phase-ce89798caa160a73Pharma Surgeen2026-06-29T10:25:50.000ZNatera and Aveta Biomics Announce Strategic Partnership Supporting Global Phase 3 Registrational Trial of APG-157 in Head and Neck Cancerhttps://www.pharmaradar360.com/article/sandoz-submits-generic-obesity-drug-applications-to-fda-by-investing-com-abc64dfcc2998b2ePharma Surgeen2026-06-29T10:16:00.000ZSandoz submits generic obesity drug applications to FDA By Investing.comhttps://www.pharmaradar360.com/article/sandoz-submits-generic-obesity-drug-applications-to-fda-6165bc74451c304ePharma Surgeen2026-06-29T10:15:41.000ZSandoz submits generic obesity drug applications to FDAhttps://www.pharmaradar360.com/article/building-an-ai-native-pharmaceutical-enterprise-lupin-s-blueprint-for-intelligen-ca5ea977d5f36000Pharma Surgeen2026-06-29T10:10:33.000ZBuilding an AI-native pharmaceutical enterprise: Lupin’s blueprint for intelligent transformation - Lupin | Perspectivehttps://www.pharmaradar360.com/article/natera-partners-with-aveta-for-phase-3-head-and-neck-cancer-trial-by-investing-c-ffe476b8b139d9d2Pharma Surgeen2026-06-29T10:09:01.000ZNatera partners with Aveta for phase 3 head and neck cancer trial By Investing.comhttps://www.pharmaradar360.com/article/fda-clears-pen-device-for-interferon-therapy-in-polycythemia-vera-eb22487b97a4bbe7Pharma Surgeen2026-06-29T10:07:29.000ZFDA Clears Pen Device for Interferon Therapy in Polycythemia Verahttps://www.pharmaradar360.com/article/goldenwell-biotech-gwll-restates-q3-2025-and-flags-going-concern-99e79c5cc49bd449Pharma Surgeen2026-06-29T10:04:18.000ZGoldenwell Biotech (GWLL) restates Q3 2025 and flags going concernhttps://www.pharmaradar360.com/article/zymeworks-to-acquire-theravance-biopharma-inc-fd4d8568322bafcbPharma Surgeen2026-06-29T10:01:22.000ZZymeworks to Acquire Theravance Biopharma, Inc.https://www.pharmaradar360.com/article/class-4-medicines-defect-notification-brancaster-pharma-limited-benzylpenicillin-f6e60c5adaa15ef5Pharma Surgeen2026-06-29T10:00:30.000ZClass 4 Medicines Defect Notification: Brancaster Pharma Limited, Benzylpenicillin benzathine 1.2 Million I.U. and 2.4 Million I.U. powder for suspension for injection, EL(26)A/30https://www.pharmaradar360.com/article/97-62c242051db53da6Pharma Surgeen2026-06-29T10:00:00.000Z日本新薬硬式野球部「第97回 都市対抗野球大会」に京都市代表として出場決定https://www.pharmaradar360.com/article/natera-joins-aveta-s-global-phase-3-head-and-neck-cancer-trial-37b8b133c9687a49Pharma Surgeen2026-06-29T10:00:00.000ZNatera joins Aveta's global Phase 3 head and neck cancer trialhttps://www.pharmaradar360.com/article/thai-fda-and-us-officials-convene-to-tighten-pesticide-checks-on-imported-produc-b9ffa5a6efc4a0ddPharma Surgeen2026-06-29T09:55:00.000ZThai FDA and US Officials Convene to Tighten Pesticide Checks on Imported Producehttps://www.pharmaradar360.com/article/national-flu-and-covid-19-surveillance-report-week-27-report-data-to-week-26-dat-d3a0d7bfc7b6a338Pharma Surgeen2026-06-29T09:50:54.000ZNational flu and COVID-19 surveillance report, week 27 report: data to week 26 (data up to 28 June 2026)https://www.pharmaradar360.com/article/china-emerging-a-global-leader-in-biotech-business-5c4fd427181a9709Pharma Surgeen2026-06-29T09:41:47.000ZChina ‘emerging a global leader’ in biotech businesshttps://www.pharmaradar360.com/article/meningococcal-b-menb-time-limited-vaccination-offer-c40ee43363d9a479Pharma Surgeen2026-06-29T09:41:42.000ZMeningococcal B (MenB) time limited vaccination offerhttps://www.pharmaradar360.com/article/meningococcal-b-menb-time-limited-vaccination-offer-information-for-healthcare-p-a9d27fb6d5e14baePharma Surgeen2026-06-29T09:41:39.000ZMeningococcal B (MenB) time limited vaccination offer: information for healthcare practitionershttps://www.pharmaradar360.com/article/national-flu-and-covid-19-surveillance-report-week-31-report-data-to-week-30-dat-a3fb4f87cd2afcf2Pharma Surgeen2026-06-29T09:37:23.000ZNational flu and COVID-19 surveillance report, week 31 report: data to week 30 (data up to 26 July 2026)https://www.pharmaradar360.com/article/weekly-all-cause-mortality-surveillance-week-ending-26-july-2026-e8a5763a98861b0ePharma Surgeen2026-06-29T09:37:12.000ZWeekly all-cause mortality surveillance: week ending 26 July 2026https://www.pharmaradar360.com/article/national-norovirus-and-rotavirus-report-week-31-report-data-to-week-30-26-july-2-382af7c5ca707f23Pharma Surgeen2026-06-29T09:37:03.000ZNational Norovirus and Rotavirus Report, week 31 report: data to week 30 (26 July 2026)https://www.pharmaradar360.com/article/tuberculosis-in-england-national-quarterly-report-q2-2026-7c808e6c9251c844Pharma Surgeen2026-06-29T09:36:54.000ZTuberculosis in England national quarterly report: Q2 2026https://www.pharmaradar360.com/article/fda-set-to-review-sandoz-s-generic-glp-1s-8a1d0a8a27a6c458Pharma Surgeen2026-06-29T09:33:43.000ZFDA set to review Sandoz's generic GLP-1shttps://www.pharmaradar360.com/article/biotech-investor-pumps-the-brakes-on-ai-drug-discovery-88d76ca530f3fd4cPharma Surgeen2026-06-29T09:30:00.000ZBiotech Investor Pumps the Brakes on AI Drug Discoveryhttps://www.pharmaradar360.com/article/enterprise-value-to-revenue-forward-of-kubota-pharmaceutical-holdings-co-ltd-tse-7e409513fcbca4cfPharma Surgeen2026-06-29T09:22:00.000ZEnterprise value to revenue forward of Kubota Pharmaceutical Holdings Co. Ltd. – TSE:4596https://www.pharmaradar360.com/article/french-biotech-company-ipsen-to-buy-kartos-therapeutics-for-450-million-c236f2e8484f9816Pharma Surgeen2026-06-29T09:21:17.000ZFrench biotech company Ipsen to buy Kartos Therapeutics for $450 millionhttps://www.pharmaradar360.com/article/shiga-toxin-producing-escherichia-coli-how-to-avoid-and-treat-005c4cafd7701d69Pharma Surgeen2026-06-29T09:18:19.000ZShiga toxin-producing Escherichia coli: how to avoid and treathttps://www.pharmaradar360.com/article/regulatory-round-up-29-june-2026-5766f4452813c0e6Pharma Surgeen2026-06-29T09:17:59.000ZRegulatory round-up: 29 June 2026https://www.pharmaradar360.com/article/us-texas-biotech-firm-to-build-noah-s-ark-for-endangered-species-fd6262a7ebfd0245Pharma Surgeen2026-06-29T09:17:54.000ZUS, Texas biotech firm to build 'Noah's Ark' for endangered specieshttps://www.pharmaradar360.com/article/enterprise-value-to-ebitda-forward-of-shaanxi-micot-pharmaceutical-technology-co-a3cd4c8590176ce4Pharma Surgeen2026-06-29T09:14:18.000ZEnterprise value to EBITDA forward of Shaanxi Micot Pharmaceutical Technology Co., Ltd. Class H – HKEX:2335https://www.pharmaradar360.com/article/fda-issues-complete-response-letter-to-sobi-s-nasp-for-gout-a6241daad60686edPharma Surgeen2026-06-29T09:10:50.000ZFDA issues complete response letter to Sobi’s NASP for gouthttps://www.pharmaradar360.com/article/ever-supreme-launches-phase-iia-clinical-trial-for-car001-accelerating-global-ma-a9a562bafcc575a0Pharma Surgeen2026-06-29T09:09:05.000ZEver Supreme Launches Phase IIa Clinical Trial for CAR001, Accelerating Global Market Expansionhttps://www.pharmaradar360.com/article/ema-recommends-approval-of-hopledo-for-parkinson-s-disease-4d70e6bcab6c9805Pharma Surgeen2026-06-29T09:05:20.000ZEMA Recommends Approval of Hopledo for Parkinson's Diseasehttps://www.pharmaradar360.com/article/dhsc-evaluation-strategy-2026-e8e86cb6f5db9997Pharma Surgeen2026-06-29T09:00:01.000ZDHSC evaluation strategy 2026https://www.pharmaradar360.com/article/samsung-bioepis-announced-on-the-29th-that-it-proved-its-equivalence-with-the-or-2c5856e5a312f251Pharma Surgeen2026-06-29T08:52:25.000ZSamsung Bioepis announced on the 29th that it proved its equivalence with the original drug in eachhttps://www.pharmaradar360.com/article/abbvie-receives-positive-chmp-opinion-for-upadacitinib-for-the-treatment-of-adul-e45ab85080f951f1Pharma Surgeen2026-06-29T08:49:00.000ZAbbVie Receives Positive CHMP Opinion for Upadacitinib for the Treatment of Adults and Adolescents with Severe Alopecia Areatahttps://www.pharmaradar360.com/article/nearly-400-antibiotic-resistant-infections-each-week-in-2024-bc908d04a513c635Pharma Surgeen2026-06-29T08:41:15.000ZNearly 400 antibiotic-resistant infections each week in 2024https://www.pharmaradar360.com/article/the-u-s-china-biotech-crackdown-may-hurt-the-scientists-america-needs-the-most-f89110c4fc3c0204Pharma Surgeen2026-06-29T08:31:23.000ZThe U.S.-China biotech crackdown may hurt the scientists America needs the mosthttps://www.pharmaradar360.com/article/xerafy-smart-rfid-label-for-healthcare-and-pharmaceutical-packagi-c14bf6607a360efbPharma Surgeen2026-06-29T08:24:55.000ZXerafy Smart RFID Label for Healthcare and Pharmaceutical Packagihttps://www.pharmaradar360.com/article/5-biotech-stocks-that-skyrocketed-105-to-235-twst-indv-mirm-more-c07d9568bbe44f74Pharma Surgeen2026-06-29T08:18:00.000Z5 Biotech Stocks That Skyrocketed 105% To 235% — TWST, INDV, MIRM & Morehttps://www.pharmaradar360.com/article/seers-wins-fda-510-k-for-mobicare-speeds-push-into-us-medicare-market-chosunbiz-67c32bb90bf9bc39Pharma Surgeen2026-06-29T08:14:00.000ZSeers wins FDA 510(k) for mobiCARE, speeds push into US Medicare market - CHOSUNBIZhttps://www.pharmaradar360.com/article/french-biotech-company-ipsen-to-buy-kartos-therapeutics-for-450-million-da0440d7131f9c4fPharma Surgeen2026-06-29T08:11:15.000ZFrench biotech company Ipsen to buy Kartos Therapeutics for $450 millionhttps://www.pharmaradar360.com/article/telitacicept-improves-clinical-response-but-increases-infection-and-hypogammaglo-0e03eede59c1bebcPharma Surgeen2026-06-29T08:08:51.000ZTelitacicept Improves Clinical Response but Increases Infection and Hypogammaglobulinemia Risk in Adults with Active SLE: Phase 3 Trial Resultshttps://www.pharmaradar360.com/article/biovitrum-falls-3-after-fda-declines-approval-for-gout-therapy-by-investing-com-f1536857f07d0287Pharma Surgeen2026-06-29T08:08:42.000ZBiovitrum falls 3% after FDA declines approval for gout therapy By Investing.comhttps://www.pharmaradar360.com/article/biotech-veterans-aim-to-build-startups-from-the-ground-up-at-capehaven-cc4f29ef7d5a5999Pharma Surgeen2026-06-29T08:00:49.000ZBiotech veterans aim to build startups from the ground up at CapeHavenhttps://www.pharmaradar360.com/article/china-closing-in-but-us-leads-in-biotech-quality-commercial-reach-survey-finds-7a29f870165688e5Pharma Surgeen2026-06-29T08:00:00.000ZChina closing in but US leads in biotech quality, commercial reach, survey findshttps://www.pharmaradar360.com/article/abbvie-broadens-immunology-focus-with-10-9-billion-apogee-deal-2034f7f44469a4b8Pharma Surgeen2026-06-29T08:00:00.000ZAbbVie broadens immunology focus with $10.9 billion Apogee dealhttps://www.pharmaradar360.com/article/target-trial-emulation-using-french-ms-registry-data-replicated-rct-treatment-ef-055b90da33ccbf00Pharma Surgeen2026-06-29T07:43:24.000ZTarget trial emulation using French MS registry data replicated RCT treatment effects on relapse rate and EDSS progression, but not consistently on MRI outcomes, in patients with multiple sclerosis initiating disease-modifying therapieshttps://www.pharmaradar360.com/article/bio-usa-2026-galux-pushes-ai-protein-design-toward-bigger-global-pharma-deals-c9115584db8c308bPharma Surgeen2026-06-29T07:41:38.000Z[BIO USA 2026] Galux pushes AI protein design toward bigger global pharma dealshttps://www.pharmaradar360.com/article/samsung-bioepis-demonstrates-equivalence-in-phase-1-and-3-trials-of-keytruda-bio-c48435a97e714463Pharma Surgeen2026-06-29T07:37:41.000ZSamsung Bioepis Demonstrates Equivalence in Phase 1 and 3 Trials of Keytruda Biosimilarhttps://www.pharmaradar360.com/article/samsung-bioepis-announces-positive-preliminary-phase-1-and-phase-3-data-for-sb27-75c1d3b49b057566Pharma Surgeen2026-06-29T07:36:44.000ZSamsung Bioepis Announces Positive Preliminary Phase 1 and Phase 3 Data for SB27, a Proposed Biosimilar to Keytruda (Pembrolizumab) – News Hubhttps://www.pharmaradar360.com/article/mdd-class-ii-hybrid-guidewire-fa122de36442cd71Pharma Surgeen2026-06-29T07:35:13.000ZΑνάκληση των παρτίδων του παρακάτω πίνακα του Ιατροτεχνολογικού προϊόντος κατηγορίας MDD Class IIΙ, HYBRID Guidewirehttps://www.pharmaradar360.com/article/enterprise-value-to-ebit-forward-of-vytrus-biotech-sa-bme-vyt-6a6429a317286a00Pharma Surgeen2026-06-29T07:22:26.000ZEnterprise value to EBIT forward of Vytrus Biotech SA – BME:VYThttps://www.pharmaradar360.com/article/swiss-pharma-at-risk-of-us-trade-investigation-industry-body-says-5e2839a6649fa359Pharma Surgeen2026-06-29T07:22:20.000ZSwiss pharma at risk of US trade investigation, industry body sayshttps://www.pharmaradar360.com/article/abbvie-receives-positive-chmp-opinion-for-upadacitinib-rinvoq-for-the-treatment-930a6b4ba0e326a1Pharma Surgeen2026-06-29T07:10:00.000ZAbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults and Adolescents with Severe Alopecia Areatahttps://www.pharmaradar360.com/article/the-global-push-to-reduce-animal-testing-in-drug-development-8afd5b2c2daecdcaPharma Surgeen2026-06-29T07:05:12.000ZThe global push to reduce animal testing in drug developmenthttps://www.pharmaradar360.com/article/xerafy-smart-rfid-label-for-healthcare-and-pharmaceutical-packaging-to-be-featur-58d579400d913fdaPharma Surgeen2026-06-29T07:04:35.000ZXerafy Smart RFID Label for Healthcare and Pharmaceutical Packaging to Be Featured by AIPIA at CPHI South Easthttps://www.pharmaradar360.com/article/abbvie-receives-positive-chmp-opinion-for-upadacitinib-rinvoq-for-the-treatment-23135c16d763494cPharma Surgeen2026-06-29T07:00:00.000ZAbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults and Adolescents with Non-segmental Vitiligohttps://www.pharmaradar360.com/article/zambon-and-amneal-announce-positive-chmp-opinion-for-hopledo-ipx203-for-adults-w-b03eeb2074a19526Pharma Surgeen2026-06-29T07:00:00.000ZZambon and Amneal Announce Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuationshttps://www.pharmaradar360.com/article/infigratinib-shows-2-1-cm-year-height-gain-in-achondroplasia-trial-b3a09db71d87f633Pharma Surgeen2026-06-29T06:48:08.000ZInfigratinib Shows +2.1 cm/year Height Gain in Achondroplasia Trialhttps://www.pharmaradar360.com/article/etfs-investing-in-shanghai-micurx-pharmaceutical-co-ltd-class-a-stocks-f33f8815c61b6f92Pharma Surgeen2026-06-29T06:43:15.000ZETFs Investing in Shanghai MicuRx Pharmaceutical Co., Ltd. Class A Stockshttps://www.pharmaradar360.com/article/haisco-pharmaceutical-group-co-ltd-class-a-actuals-estimates-szse-002653-6fe22a422fee619ePharma Surgeen2026-06-29T06:37:04.000ZHaisco Pharmaceutical Group Co. Ltd. Class A Actuals & Estimates (SZSE:002653)https://www.pharmaradar360.com/article/enterprise-value-to-ebitda-forward-of-kane-biotech-inc-tsxv-kne-5e2d9911ebfb5b04Pharma Surgeen2026-06-29T06:09:18.000ZEnterprise value to EBITDA forward of Kane Biotech Inc. – TSXV:KNEhttps://www.pharmaradar360.com/article/last-week-in-review-374e9b49d21e40efPharma Surgeen2026-06-29T05:24:09.000ZLAST WEEK IN REVIEWhttps://www.pharmaradar360.com/article/lecanemab-alzheimer-s-drug-shows-limited-benefit-experts-urge-cautious-use-f2a96b800fd9002ePharma Surgeen2026-06-29T05:06:00.000ZLecanemab Alzheimer’s drug shows limited benefit, experts urge cautious usehttps://www.pharmaradar360.com/article/roche-announces-the-launch-of-axelios-1-a-transformative-next-generation-sequenc-73de3f3a61c17897Pharma Surgeen2026-06-29T05:00:00.000ZRoche announces the launch of AXELIOS 1, a transformative next-generation sequencing platformhttps://www.pharmaradar360.com/article/aribio-completes-main-phase-3-dosing-for-oral-alzheimer-s-drug-ar1001-topline-da-d2f56910e7924a13Pharma Surgeen2026-06-29T04:48:56.000ZAriBio completes main phase 3 dosing for oral Alzheimer's drug AR1001, topline data due this fallhttps://www.pharmaradar360.com/article/sls-ibrx-eye-green-month-as-biotech-etf-gains-steam-analyst-sees-continued-oppor-6a1aa66cf3396998Pharma Surgeen2026-06-29T04:40:00.000ZSLS, IBRX Eye Green Month As Biotech ETF Gains Steam: Analyst Sees ‘Continued Opportunities’ In Immuno-Oncologyhttps://www.pharmaradar360.com/article/gc-wellbeing-secures-korean-rights-to-next-gen-fat-dissolving-injection-ahead-of-10f2843623db7795Pharma Surgeen2026-06-29T04:25:02.000ZGC Wellbeing secures Korean rights to next-gen fat-dissolving injection ahead of US phase 3 trialhttps://www.pharmaradar360.com/article/china-s-burgeoning-biopharmaceutical-competitiveness-demands-a-us-response-repor-0cba935ea96ccef6Pharma Surgeen2026-06-29T04:05:07.000ZChina’s Burgeoning Biopharmaceutical Competitiveness Demands a US Response | Reports & Briefings | Jun 29, 2026https://www.pharmaradar360.com/article/inside-lilly-s-biotech-startup-factory-eae069b2732e19a9Pharma Surgeen2026-06-29T03:57:43.000ZInside Lilly's biotech startup factoryhttps://www.pharmaradar360.com/article/sk-chemicals-j2h-biotech-sign-loi-to-co-develop-mash-therapy-7e391c8ca0f64240Pharma Surgeen2026-06-29T03:28:15.000ZSK chemicals, J2H Biotech sign LOI to co-develop MASH therapyhttps://www.pharmaradar360.com/article/shinsa-information-regarding-explanations-to-driver-mutations-in-the-development-6e813271093e8f27Pharma Surgeen2026-06-29T03:00:00.000Z[SHINSA]Information Regarding Explanations to Driver Mutations in the Development of Anti-cancer Drugs（Early Consideration）posted.https://www.pharmaradar360.com/article/price-to-book-forward-of-burning-rock-biotech-ltd-sponsored-adr-dus-6bu0-c933e936b17b5dcePharma Surgeen2026-06-29T02:57:41.000ZPrice to book forward of Burning Rock Biotech Ltd. Sponsored ADR – DUS:6BU0https://www.pharmaradar360.com/article/how-a-regional-pharmaceutical-leader-maintained-compliance-through-divestiture-w-508dbf48f3250db6Pharma Surgeen2026-06-29T02:39:37.000ZHow A Regional Pharmaceutical Leader Maintained Compliance Through Divestiture Without Disrupting Operationshttps://www.pharmaradar360.com/article/star-therapeutics-to-present-complete-data-from-phase-1-2-multidose-study-of-vga-34fb314ef4ca0d8aPharma Surgeen2026-06-29T02:20:52.000ZStar Therapeutics to Present Complete Data from Phase 1/2 Multidose Study of VGA039 in Von Willebrand Disease at ISTH 2026 Congresshttps://www.pharmaradar360.com/article/interview-biotech-act-rapporteur-defends-evidence-first-approach-to-spc-debate-29003b347e33c750Pharma Surgeen2026-06-29T02:14:56.000ZINTERVIEW: Biotech Act rapporteur defends evidence-first approach to SPC debatehttps://www.pharmaradar360.com/article/etfs-investing-in-binh-dinh-pharmaceutical-medical-equipment-jsc-stocks-1e39be3fd72fd6c3Pharma Surgeen2026-06-29T02:12:43.000ZETFs Investing in Binh Dinh Pharmaceutical & Medical Equipment JSC Stockshttps://www.pharmaradar360.com/article/autotelic-bio-wins-fda-approval-for-atb-101-phase-1-trial-in-us-88621b2b8148e088Pharma Surgeen2026-06-29T02:05:44.000ZAutotelic Bio Wins FDA Approval for ATB-101 Phase 1 Trial in UShttps://www.pharmaradar360.com/article/gc-wellbeing-secures-rights-to-next-gen-fat-dissolving-injection-f70810f79c57b5b2Pharma Surgeen2026-06-29T01:55:19.000ZGC Wellbeing secures rights to next-gen fat-dissolving injectionhttps://www.pharmaradar360.com/article/csl-halts-tavneos-drug-sale-following-eu-regulatory-setback-50c24fe8aa2f4bacPharma Surgeen2026-06-29T01:54:00.000ZCSL halts Tavneos drug sale following EU regulatory setbackhttps://www.pharmaradar360.com/article/lupin-receives-tentative-approval-from-u-s-fda-for-enzalutamide-tablets-696686ad9d3f3954Pharma Surgeen2026-06-29T01:34:33.000ZLupin Receives Tentative Approval from U.S. FDA for Enzalutamide Tabletshttps://www.pharmaradar360.com/article/poland-calls-for-unified-eu-strategy-on-biotech-and-critical-medicines-49ee9567e12dd19ePharma Surgeen2026-06-29T01:04:55.000ZPoland calls for unified EU strategy on biotech and critical medicineshttps://www.pharmaradar360.com/article/news-biotech-job-funding-growth-signal-rising-space-demand-mortgage-applications-51fe1d7b26279ec7Pharma Surgeen2026-06-29T01:00:23.000ZNews | Biotech job, funding growth signal rising space demand; Mortgage applications increase; Construction employment slowshttps://www.pharmaradar360.com/article/joint-research-with-tohoku-universityestablishment-of-a-collaborative-research-p-e30c5425535caecePharma Surgeen2026-06-29T01:00:00.000ZJoint Research with Tohoku UniversityEstablishment of a Collaborative Research Program on Water Turnover and Total Conditioninghttps://www.pharmaradar360.com/article/ellagic-acid-market-forecast-points-higher-toward-2035-driven-by-pharmaceutical-5a942848908492b0Pharma Surgeen2026-06-29T00:36:34.000ZEllagic Acid Market Forecast Points Higher Toward 2035, Driven by Pharmaceutical and Bioprocessing Demandhttps://www.pharmaradar360.com/article/aribio-completes-patient-dosing-in-global-phase-3-trial-of-oral-alzheimer-s-drug-cc4248343c9653c4Pharma Surgeen2026-06-29T00:22:54.000ZAriBio Completes Patient Dosing in Global Phase 3 Trial of Oral Alzheimer's Drughttps://www.pharmaradar360.com/article/aribio-completes-global-phase-3-trials-for-oral-alzheimers-drug-ar1001-a8c44deefaa2ee63Pharma Surgeen2026-06-29T00:20:00.000ZAribio Completes Global Phase 3 Trials for Oral Alzheimers Drug AR1001https://www.pharmaradar360.com/article/kailera-appoints-new-chief-corporate-affairs-officer-8409eaba6a6d01a2Pharma Surgeen2026-06-29T00:03:23.000ZKailera Appoints New Chief Corporate Affairs Officerhttps://www.pharmaradar360.com/article/astrazeneca-filed-form-6-k-e02d426260ca6839Pharma Surgeen2026-06-29T00:00:00.000ZAstraZeneca filed Form 6-Khttps://www.pharmaradar360.com/article/gsk-filed-form-6-k-086075fc0ef5184ePharma Surgeen2026-06-29T00:00:00.000ZGSK filed Form 6-Khttps://www.pharmaradar360.com/article/view-all-in-depth-f57711315ba4a48ePharma Surgeen2026-06-29T00:00:00.000ZView all in-depthhttps://www.pharmaradar360.com/article/natco-records-e2-82-b9816-9-crore-consolidated-revenue-and-e2-82-b9269-0-crore-o-dac4bd80d7c8b8acPharma Surgeen2026-06-29T00:00:00.000Znatco records %e2%82%b9816 9 crore consolidated revenue and %e2%82%b9269 0 crore of profit after tax for q4 fy26 and %e2%82%b94375 9 crore of revenue %e2%82%b91418 5 crore profit after tax for fy26https://www.pharmaradar360.com/article/natco-records-e2-82-b9705-4-crore-consolidated-revenue-and-e2-82-b9151-3-crore-o-af6f730bddf8b15cPharma Surgeen2026-06-29T00:00:00.000Znatco records %e2%82%b9705 4 crore consolidated revenue and %e2%82%b9151 3 crore of profit after tax for q3fy26https://www.pharmaradar360.com/article/natco-records-e2-82-b91463-crore-consolidated-revenue-and-e2-82-b9517-9-crore-of-2f81d72aeda757afPharma Surgeen2026-06-29T00:00:00.000Znatco records %e2%82%b91463 crore consolidated revenue and %e2%82%b9517 9 crore of profit after tax for q2fy26https://www.pharmaradar360.com/article/natco-receives-tentative-approval-for-erdafitinib-tablets-generic-of-balversa-fr-7218f0fce9bb4b35Pharma Surgeen2026-06-29T00:00:00.000Znatco receives tentative approval for erdafitinib tablets generic of balversa from the united states food and drug administration u s fdahttps://www.pharmaradar360.com/article/natco-receives-approval-from-central-drug-standard-control-organisation-cdsco-fo-a56fc9ffdfd43cafPharma Surgeen2026-06-29T00:00:00.000Znatco receives approval from central drug standard control organisation cdsco for semaglutide in indiahttps://www.pharmaradar360.com/article/natco-pharma-limited-api-unit-in-chennai-receives-establishment-inspection-repor-1386550ec89e33afPharma Surgeen2026-06-29T00:00:00.000Znatco pharma limited api unit in chennai receives establishment inspection report eir from u s fdahttps://www.pharmaradar360.com/article/natco-pharma-launches-semaglutide-generic-injection-multi-dose-vials-in-india-at-e687ded803cffb28Pharma Surgeen2026-06-29T00:00:00.000Znatco pharma launches semaglutide generic injection multi dose vials in india at the most affordable price starting from mrp inr 1290https://www.pharmaradar360.com/article/natco-announces-launch-of-pomalidomide-capsules-generic-of-pomalyst-in-the-u-s-m-bf04d3f53448505dPharma Surgeen2026-06-29T00:00:00.000Znatco announces launch of pomalidomide capsules generic of pomalyst in the u s markethttps://www.pharmaradar360.com/article/natco-announces-launch-of-its-everolimus-tablets-1-mg-generic-of-zortress-a8eb9db27b332a32Pharma Surgeen2026-06-29T00:00:00.000Znatco announces launch of its everolimus tablets 1 mg generic of zortresshttps://www.pharmaradar360.com/article/natco-and-lupin-receive-approval-from-u-s-fda-for-eribulin-mesylate-injection-205be3b6295090d1Pharma Surgeen2026-06-29T00:00:00.000Znatco and lupin receive approval from u s fda for eribulin mesylate injectionhttps://www.pharmaradar360.com/article/intimation-under-regulation-30-of-sebi-listing-obligations-and-disclosure-requir-83766fe81e3f3700Pharma Surgeen2026-06-29T00:00:00.000Zintimation under regulation 30 of sebi listing obligations and disclosure requirements regulations 2015 2https://www.pharmaradar360.com/article/disclosure-under-regulation-30-of-the-sebi-listing-obligations-and-disclosure-re-56d3862721574f4aPharma Surgeen2026-06-29T00:00:00.000Zdisclosure under regulation 30 of the sebi listing obligations and disclosure requirements regulations 2015https://www.pharmaradar360.com/article/adcock-ingram-completes-delisting-from-jse-natco-pharma-acquires-35-75-stake-27603280f3fda9e4Pharma Surgeen2026-06-29T00:00:00.000Zadcock ingram completes delisting from jse natco pharma acquires 35 75 stakehttps://www.pharmaradar360.com/article/home-page-a7c89ae8df1d2332Pharma Surgeen2026-06-29T00:00:00.000ZHome pagehttps://www.pharmaradar360.com/article/medicaid-program-community-engagement-requirement-for-certain-individuals-1d26d189434b3bfePharma Surgeen2026-06-29T00:00:00.000ZMedicaid Program; Community Engagement Requirement for Certain Individualshttps://www.pharmaradar360.com/article/medical-devices-orthopedic-devices-classification-of-the-medial-knee-implanted-s-fd100919342a44b7Pharma Surgeen2026-06-29T00:00:00.000ZMedical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock Absorberhttps://www.pharmaradar360.com/article/cellular-tissue-and-gene-therapies-advisory-committee-notice-of-meeting-establis-294eb2e757dd644ePharma Surgeen2026-06-29T00:00:00.000ZCellular, Tissue, and Gene Therapies Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments-Biologics License Application (BLA) 125842 From Capricor, Inc. for Deramiocel (Human Allogeneic Cardiosphere-Derived Cells)https://www.pharmaradar360.com/article/center-for-scientific-review-notice-of-closed-meetings-d5bbe70ce274cde2Pharma Surgeen2026-06-29T00:00:00.000ZCenter for Scientific Review; Notice of Closed Meetingshttps://www.pharmaradar360.com/article/agency-information-collection-activities-submission-to-omb-for-review-and-approv-1d3e91a0a7e5b991Pharma Surgeen2026-06-29T00:00:00.000ZAgency Information Collection Activities: Submission to OMB for Review and Approval; Public Comment Request; Rural Health Care Coordination Program Performance Improvement Measures, OMB No. 0906-0024-Revisionhttps://www.pharmaradar360.com/article/advisory-committee-on-breast-cancer-in-young-women-notice-of-charter-renewal-0634329210e3cc44Pharma Surgeen2026-06-29T00:00:00.000ZAdvisory Committee on Breast Cancer in Young Women; Notice of Charter Renewalhttps://www.pharmaradar360.com/article/establishment-registration-and-product-listing-for-tobacco-products-6e6b342c075c962aPharma Surgeen2026-06-29T00:00:00.000ZEstablishment Registration and Product Listing for Tobacco Productshttps://www.pharmaradar360.com/article/office-of-the-director-national-institutes-of-health-notice-of-closed-meeting-46b7ba8a4b47d3b3Pharma Surgeen2026-06-29T00:00:00.000ZOffice of the Director, National Institutes of Health; Notice of Closed Meetinghttps://www.pharmaradar360.com/article/determination-of-regulatory-review-period-for-purposes-of-patent-extension-vyale-8ca1eed56c7ae4d1Pharma Surgeen2026-06-29T00:00:00.000ZDetermination of Regulatory Review Period for Purposes of Patent Extension; VYALEVhttps://www.pharmaradar360.com/article/agency-information-collection-activities-submission-for-office-of-management-and-bc4ab3d843985ba0Pharma Surgeen2026-06-29T00:00:00.000ZAgency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; New Animal Drugs for Minor Use and Minor Specieshttps://www.pharmaradar360.com/article/national-heart-lung-and-blood-institute-notice-of-closed-meeting-21960810b2679d58Pharma Surgeen2026-06-29T00:00:00.000ZNational Heart, Lung, and Blood Institute; Notice of Closed Meetinghttps://www.pharmaradar360.com/article/national-institute-of-environmental-health-sciences-notice-of-meeting-6029d027a108b490Pharma Surgeen2026-06-29T00:00:00.000ZNational Institute of Environmental Health Sciences; Notice of Meetinghttps://www.pharmaradar360.com/article/center-for-scientific-review-amended-notice-of-meeting-425f2800aae3c69bPharma Surgeen2026-06-29T00:00:00.000ZCenter for Scientific Review; Amended Notice of Meetinghttps://www.pharmaradar360.com/article/cleveland-clinic-tackles-hunger-housing-and-maternal-health-5afafb39af03da95Pharma Surgeen2026-06-29T00:00:00.000ZCleveland Clinic Tackles Hunger, Housing and Maternal Healthhttps://www.pharmaradar360.com/article/united-therapeutics-corporation-announces-fda-approval-of-the-lungfxtm-device-fo-66b56bf06da7b7abPharma Surgeen2026-06-29T00:00:00.000ZUnited Therapeutics Corporation Announces FDA Approval of the LungFX™ Device for Centralized Ex Vivo Lung Perfusionhttps://www.pharmaradar360.com/article/build-confidence-in-your-ability-to-get-drug-calculations-right-8268c69bff92193fPharma Surgeen2026-06-29T00:00:00.000ZBuild confidence in your ability to get drug calculations righthttps://www.pharmaradar360.com/article/association-of-periodontitis-severity-and-tooth-loss-with-gastric-cancer-5e0c45e3fad951fbPharma Surgeen2026-06-29T00:00:00.000ZAssociation of periodontitis severity and tooth loss with gastric cancerhttps://www.pharmaradar360.com/article/machine-perfusion-distribution-across-clinical-phenotypes-in-kidney-transplantat-e563b24d2332a2a9Pharma Surgeen2026-06-29T00:00:00.000ZMachine perfusion distribution across clinical phenotypes in kidney transplantation: A national cohort study using unsupervised clusteringhttps://www.pharmaradar360.com/article/occupational-stress-glossophobia-and-impostor-cognitions-an-integrative-clinical-16ea408d30aba3b8Pharma Surgeen2026-06-29T00:00:00.000ZOccupational stress, Glossophobia, and Impostor Cognitions: An Integrative Clinical Case Study of Anxiety and Maladaptive Psychotropic Copinghttps://www.pharmaradar360.com/article/optimizing-vehicle-loading-to-improve-operational-safety-at-kmp-dharma-ferry-vii-b6d093d14455f2c3Pharma Surgeen2026-06-29T00:00:00.000ZOptimizing Vehicle Loading to Improve Operational Safety at KMP. Dharma Ferry VIIIhttps://www.pharmaradar360.com/article/protective-effects-of-tricin-against-oxldl-stimulated-inflammatory-and-oxidative-b9f5132110d402ddPharma Surgeen2026-06-29T00:00:00.000ZProtective Effects of Tricin Against Oxldl-Stimulated Inflammatory and Oxidative Stress Responses in RAW 264.7 Cellshttps://www.pharmaradar360.com/article/nutritionally-improved-traditional-recipes-and-fortified-infant-flours-to-increa-92117a79ec6e8323Pharma Surgeen2026-06-29T00:00:00.000ZNutritionally Improved Traditional Recipes and Fortified Infant Flours to Increase the Nutritional and Energy Intake in 6–11-Month-Old Infants in Rural Niger: A Randomized Controlled Trialhttps://www.pharmaradar360.com/article/time-to-complete-clinical-recovery-and-its-predictors-in-bell-s-palsy-patients-r-b39279aea22e9c79Pharma Surgeen2026-06-29T00:00:00.000ZTime to Complete Clinical Recovery and Its Predictors in Bell’s Palsy Patients Receiving Acupuncture: A Prospective Cohort Studyhttps://www.pharmaradar360.com/article/systematic-review-and-single-arm-meta-analysis-of-the-clinical-value-of-multidis-4faa6c6d5122fde8Pharma Surgeen2026-06-29T00:00:00.000ZSystematic review and single-arm meta-analysis of the clinical value of multidisciplinary team-based multimodal interventions in pulmonary nodule managementhttps://www.pharmaradar360.com/article/brca1-2-pathogenic-variants-in-a-turkish-cohort-clinical-spectrum-novel-truncati-02a0f3583716576fPharma Surgeen2026-06-29T00:00:00.000ZBRCA1/2 Pathogenic Variants in a Turkish Cohort: Clinical Spectrum, Novel Truncating Variants, and Non-Canonical Cancers in the Aegean Regionhttps://www.pharmaradar360.com/article/the-relationship-between-cancer-worry-and-gynecological-cancer-awareness-in-wome-edf272e262648647Pharma Surgeen2026-06-29T00:00:00.000ZThe Relationship Between Cancer Worry and Gynecological Cancer Awareness in Women and Affecting Factorshttps://www.pharmaradar360.com/article/assessment-of-the-current-dental-condition-and-treatment-needs-of-permanent-firs-251d8af80c5146c5Pharma Surgeen2026-06-29T00:00:00.000ZAssessment of the Current Dental Condition and Treatment Needs of Permanent First Molars in University Studentshttps://www.pharmaradar360.com/article/social-media-usage-resilience-and-coping-strategies-in-young-adults-a-multidimen-21bf3da52142208dPharma Surgeen2026-06-29T00:00:00.000ZSocial Media Usage, Resilience, and Coping Strategies in Young Adults: A Multidimensional Analysishttps://www.pharmaradar360.com/article/modernizing-tradition-comprehensive-documentation-and-cad-based-product-redesign-f5feb506c136fdc9Pharma Surgeen2026-06-29T00:00:00.000ZModernizing Tradition: Comprehensive Documentation and CAD-Based Product Redesign of Pulla Chappal Crafthttps://www.pharmaradar360.com/article/chitosan-nanoparticle-based-mucoadhesive-and-mucopenetrating-vaginal-drug-delive-8d9dbfa8edf78b5bPharma Surgeen2026-06-29T00:00:00.000ZChitosan nanoparticle based mucoadhesive and mucopenetrating vaginal drug delivery systemshttps://www.pharmaradar360.com/article/comparative-evaluation-of-chlorhexidine-and-cranberry-extract-as-matrix-metallop-361889558418e13dPharma Surgeen2026-06-29T00:00:00.000ZComparative Evaluation Of Chlorhexidine And Cranberry Extract As Matrix Metalloproteinase Inhibitors On Composite Resin Bond Strength: An In Vitro Studyhttps://www.pharmaradar360.com/article/a-novel-dydimnet-based-dimension-aware-deep-learning-framework-for-automated-ova-833fb6a86b74125aPharma Surgeen2026-06-29T00:00:00.000ZA Novel DyDimNet-Based Dimension-Aware Deep Learning Framework for Automated Ovarian Tumor Classification Using Ultrasound Imageshttps://www.pharmaradar360.com/article/histopathological-determinants-of-recurrence-in-odontogenic-cysts-and-tumors-imp-33ad15623571de82Pharma Surgeen2026-06-29T00:00:00.000ZHistopathological Determinants of Recurrence in Odontogenic Cysts and Tumors: Implications for Surgical Decision-Making: A Retrospective Cohort Studyhttps://www.pharmaradar360.com/article/community-pharmacists-perspectives-and-practices-on-antimicrobial-drug-use-and-r-1c90166ea26c7f24Pharma Surgeen2026-06-29T00:00:00.000ZCommunity Pharmacists' Perspectives and Practices on Antimicrobial Drug Use and Resistance: An Educational Intervention Studyhttps://www.pharmaradar360.com/article/the-accuracy-of-ai-based-chatbots-in-responding-to-routinely-asked-questions-abo-d6de07830bc0f4c3Pharma Surgeen2026-06-29T00:00:00.000ZTHE ACCURACY OF AI-BASED CHATBOTS IN RESPONDING TO ROUTINELY ASKED QUESTIONS ABOUT ORTHODONTICS: A COMPARATIVE STUDYhttps://www.pharmaradar360.com/article/awareness-and-utilisation-of-balance-assessment-tools-among-budding-physiotherap-cba635f21597f88dPharma Surgeen2026-06-29T00:00:00.000ZAwareness and Utilisation of Balance Assessment Tools Among Budding Physiotherapists for Identifying Multisensory Integration Deficits and Their Correlation with Fall Risk: A Cross-Sectional Studyhttps://www.pharmaradar360.com/article/a-study-of-clinical-profile-of-gall-stone-induced-pancreatitis-and-its-correlati-17707409caeecbcbPharma Surgeen2026-06-29T00:00:00.000ZA Study of Clinical Profile of Gall Stone Induced Pancreatitis and Its Correlation with Severity Indiceshttps://www.pharmaradar360.com/article/physiotherapy-management-of-post-operative-cellulitis-for-functional-recovery-a-c9433bcd8d2e5ddaPharma Surgeen2026-06-29T00:00:00.000ZPhysiotherapy Management of Post-Operative Cellulitis for Functional Recovery: A Case Reporthttps://www.pharmaradar360.com/article/a-study-to-assess-the-effectiveness-of-structured-teaching-programme-on-knowledg-dd6babcf58a69d99Pharma Surgeen2026-06-29T00:00:00.000ZA Study To Assess The Effectiveness of Structured Teaching Programme on Knowledge Regarding Warning Signs of Pregnancy and Its Management Among Primigravida Mother's Attending Antenatal OPD and Obs Ward at SRM MCH and RChttps://www.pharmaradar360.com/article/mitigating-freeze-thaw-and-agitation-induced-particulate-matter-formation-challe-2dffa55d49940622Pharma Surgeen2026-06-29T00:00:00.000ZMitigating Freeze-Thaw and Agitation Induced Particulate Matter Formation Challenge in Biopharmaceuticals: Formulation Strategies and Stability Assessmenthttps://www.pharmaradar360.com/article/rational-design-and-synthesis-of-covalent-krasg12c-inhibitors-as-potential-antic-2cf1b18e032c314bPharma Surgeen2026-06-29T00:00:00.000ZRational Design and Synthesis of Covalent KRASG12C Inhibitors as Potential Anticancer Agentshttps://www.pharmaradar360.com/article/preferred-modalities-on-prevention-and-management-of-iatrogenic-effects-of-ortho-ba3fb42733537873Pharma Surgeen2026-06-29T00:00:00.000ZPreferred Modalities on Prevention and Management of Iatrogenic Effects of Orthodontic Therapy Among Orthodontistshttps://www.pharmaradar360.com/article/integrative-genomic-and-clinical-profiling-of-colorectal-cancer-liver-metastases-83628322b835734dPharma Surgeen2026-06-29T00:00:00.000ZIntegrative Genomic and Clinical Profiling of Colorectal Cancer Liver Metastases to Guide Personalized Surgery and Liver Transplantationhttps://www.pharmaradar360.com/article/clinical-characteristics-and-platelet-related-predictors-of-mortality-in-patient-cc6287207f9295f3Pharma Surgeen2026-06-29T00:00:00.000ZClinical Characteristics and Platelet‑Related Predictors of Mortality in Patients With Traumatic Brain Injuryhttps://www.pharmaradar360.com/article/from-startups-to-giants-leveraging-artificial-intelligence-for-sustainable-innov-ce9fb3c947b8d9acPharma Surgeen2026-06-29T00:00:00.000ZFrom Startups to Giants: Leveraging Artificial Intelligence for Sustainable Innovation and Competitive Advantage in Pharmaceutical Marketinghttps://www.pharmaradar360.com/article/navigating-toxicity-in-lung-cancer-immunotherapy-challenges-and-advances-in-nano-dc321d9f12344886Pharma Surgeen2026-06-29T00:00:00.000ZNavigating toxicity in lung cancer immunotherapy: challenges and advances in Nano medicine drug deliveryhttps://www.pharmaradar360.com/article/the-intensive-outreach-programme-for-child-and-adolescent-eating-disorders-an-un-c98d54a7f64a4c3aPharma Surgeen2026-06-29T00:00:00.000ZThe intensive outreach programme for child and adolescent eating disorders: an uncontrolled case series of clinical characteristics and treatment outcomeshttps://www.pharmaradar360.com/article/adjunctive-optical-and-magnetic-stimulation-for-venous-and-mixed-etiology-leg-ul-087091683a758466Pharma Surgeen2026-06-29T00:00:00.000ZAdjunctive optical and magnetic stimulation for venous and mixed etiology leg ulcers: protocol for the NAZARÉ multicenter randomized controlled trialhttps://www.pharmaradar360.com/article/prospective-clinical-validation-of-targeted-long-read-sequencing-for-preimplanta-d88262c33281aaeaPharma Surgeen2026-06-29T00:00:00.000ZProspective clinical validation of targeted long-read sequencing for preimplantation genetic testing of α-thalassaemiahttps://www.pharmaradar360.com/article/comparative-efficacy-of-arthrocentesis-combined-with-different-drug-injections-f-a686903c51b40a91Pharma Surgeen2026-06-29T00:00:00.000ZComparative efficacy of arthrocentesis combined with different drug injections for arthrogenic temporomandibular disorders: a network meta-analysis of randomized trialshttps://www.pharmaradar360.com/article/timing-and-clinical-burden-of-febrile-neutropenia-and-treatment-discontinuation-32cc5a4cc0a3c221Pharma Surgeen2026-06-29T00:00:00.000ZTiming and clinical burden of febrile neutropenia and treatment discontinuation during neoadjuvant chemotherapyhttps://www.pharmaradar360.com/article/rising-trends-in-dementia-and-psychoactive-drug-related-mortality-in-the-united-e1a1069c8ee85e44Pharma Surgeen2026-06-29T00:00:00.000ZRising trends in dementia and psychoactive drug-related mortality in the United States, 2000–2023. A retrospective analysis using CDC WONDERhttps://www.pharmaradar360.com/article/efficacy-and-safety-of-single-high-dose-intravenous-ferric-carboxymaltose-in-pat-341ae191a738af6cPharma Surgeen2026-06-29T00:00:00.000ZEfficacy and safety of single high-dose intravenous ferric carboxymaltose in patients undergoing hemodialysis: a multicenter, single-arm, open-label, clinical trialhttps://www.pharmaradar360.com/article/epidemiology-and-clinical-profile-of-inflammatory-bowel-disease-in-kuwait-a-nati-c734bdb7af6384e9Pharma Surgeen2026-06-29T00:00:00.000ZEpidemiology and clinical profile of inflammatory bowel disease in Kuwait: a nationwide tertiary care (SEEF-IBD) studyhttps://www.pharmaradar360.com/article/predictive-value-of-the-novel-cardiometabolic-index-for-reduced-aerobic-capacity-40ddb7dc2192baeePharma Surgeen2026-06-29T00:00:00.000ZPredictive value of the novel cardiometabolic index for reduced aerobic capacity in patients with coronary heart disease: a clinical comparative study of 378 caseshttps://www.pharmaradar360.com/article/lipid-based-nanocarriers-for-antifungal-drug-delivery-8d8de49da5456a82Pharma Surgeen2026-06-29T00:00:00.000ZLipid-based nanocarriers for antifungal drug deliveryhttps://www.pharmaradar360.com/article/commentary-the-clinical-activity-of-nurses-in-general-practice-c96374dd84823ee0Pharma Surgeen2026-06-29T00:00:00.000ZCommentary: The clinical activity of nurses in general practicehttps://www.pharmaradar360.com/article/correction-to-effectiveness-of-a-message-service-on-child-oral-health-practice-v-1d8caf198390e90fPharma Surgeen2026-06-29T00:00:00.000ZCorrection to “Effectiveness of a message service on child oral health practice via a social media application: A randomized controlled trial”https://www.pharmaradar360.com/article/structured-guidance-for-clinical-reflection-journals-a-5-level-framework-from-da-96d7c3771c3012acPharma Surgeen2026-06-29T00:00:00.000ZStructured Guidance for Clinical Reflection Journals: A 5-Level Framework From Daily Logs to Deep Clinical Thinkinghttps://www.pharmaradar360.com/article/clinical-burnout-a-diagnosis-in-search-of-validation-7bc426058fcecb0cPharma Surgeen2026-06-29T00:00:00.000Z“Clinical Burnout”: A Diagnosis in Search of Validationhttps://www.pharmaradar360.com/article/obesity-induced-intervertebral-disk-degeneration-pathophysiology-and-clinical-im-9018f6a40ebee36bPharma Surgeen2026-06-29T00:00:00.000ZObesity-induced intervertebral disk degeneration: pathophysiology and clinical implicationshttps://www.pharmaradar360.com/article/pulsatile-fxr-agonism-66db7c0b1dda49c2Pharma Surgeen2026-06-29T00:00:00.000ZPulsatile FXR agonismhttps://www.pharmaradar360.com/article/supplemental-material-for-using-natural-language-processing-to-track-negative-em-47121ec7b531810ePharma Surgeen2026-06-29T00:00:00.000ZSupplemental Material for Using Natural Language Processing to Track Negative Emotions in the Daily Lives of Adolescentshttps://www.pharmaradar360.com/article/informing-sampling-design-for-lung-distribution-studies-using-a-pulmonary-popula-511cac742474990dPharma Surgeen2026-06-29T00:00:00.000ZInforming Sampling Design for Lung Distribution Studies Using a Pulmonary Population Minimal PBPK Modelhttps://www.pharmaradar360.com/article/bridging-solubility-stability-and-translation-advances-in-carbon-nanotube-based-c143a9ca25c8f220Pharma Surgeen2026-06-29T00:00:00.000ZBridging solubility, stability, and translation: advances in carbon nanotube–based drug delivery systemshttps://www.pharmaradar360.com/article/two-cases-of-successful-treatment-of-bleeding-esophagojejunal-varices-after-tota-c03606f4e3b2f914Pharma Surgeen2026-06-29T00:00:00.000ZTwo cases of successful treatment of bleeding esophagojejunal varices after total gastrectomy using reopenable clip hemostasishttps://www.pharmaradar360.com/article/haemodynamics-of-pre-syncope-during-carotid-sinus-massage-a-beat-to-beat-analysi-9f769a7008dfa90fPharma Surgeen2026-06-29T00:00:00.000ZHaemodynamics of (pre)syncope during carotid sinus massage: a beat-to-beat analysis of haemodynamic parameters during carotid sinus massagehttps://www.pharmaradar360.com/article/job-resignation-between-cancer-diagnosis-and-surgery-in-patients-with-gastric-an-7d043fbb3ec729edPharma Surgeen2026-06-29T00:00:00.000ZJob resignation between cancer diagnosis and surgery in patients with gastric and esophageal cancer: a multi-institutional cross-sectional studyhttps://www.pharmaradar360.com/article/clinical-characteristics-of-acute-pancreatitis-in-patients-with-inflammatory-bow-a85ee32f91271444Pharma Surgeen2026-06-29T00:00:00.000ZClinical characteristics of acute pancreatitis in patients with inflammatory bowel disease: a nationwide survey in Japanhttps://www.pharmaradar360.com/article/preventing-post-denosumab-bone-loss-with-zoledronate-a-2-year-randomized-trial-i-099c755b169e5c3dPharma Surgeen2026-06-29T00:00:00.000ZPreventing post-denosumab bone loss with zoledronate: a 2-year randomized trial in post-menopausal women without and with pre-exposure to bisphosphonateshttps://www.pharmaradar360.com/article/artificial-intelligence-equity-and-pediatric-neurodevelopmental-disorders-a-scop-7f163f43a2462f1dPharma Surgeen2026-06-29T00:00:00.000ZArtificial intelligence, equity, and pediatric neurodevelopmental disorders: A scoping review of clinical practice applicationshttps://www.pharmaradar360.com/article/prophylactic-dextrose-gel-for-neonatal-hypoglycemia-and-neurocognitive-function-a437db86a4466012Pharma Surgeen2026-06-29T00:00:00.000ZProphylactic Dextrose Gel for Neonatal Hypoglycemia and Neurocognitive Function at 6 to 7 Years of Agehttps://www.pharmaradar360.com/article/nct07674173-post-market-european-asian-registry-to-evaluate-the-minostm-stent-gr-061396157cf970bbPharma Surgeen2026-06-29T00:00:00.000ZNCT07674173: Post-market European & Asian Registry to Evaluate the Minos™ Stent-Graft and Delivery System in Abdominal Aortic Aneurysm Treatmenthttps://www.pharmaradar360.com/article/nct07672899-small-rna-trf-31-changes-in-patients-with-age-related-cataract-99bb93b1adc8025cPharma Surgeen2026-06-29T00:00:00.000ZNCT07672899: Small RNA tRF-31 Changes in Patients With Age-Related Cataracthttps://www.pharmaradar360.com/article/nct07672769-bexmarilimab-azacitidine-versus-placebo-azacitidine-in-participants-0af8223df85f329dPharma Surgeen2026-06-29T00:00:00.000ZNCT07672769: Bexmarilimab + Azacitidine Versus Placebo + Azacitidine in Participants With Treatment-naïve Higher-risk Myelodysplastic Syndromeshttps://www.pharmaradar360.com/article/nct07672639-development-and-validation-of-a-machine-learning-model-for-different-7b8a36a962bd894cPharma Surgeen2026-06-29T00:00:00.000ZNCT07672639: Development and Validation of a Machine Learning Model for Differentiating Diabetic Kidney Disease and Non-Diabetic Kidney Disease in Type 2 Diabeteshttps://www.pharmaradar360.com/article/nct07672509-multimodal-sleep-promotion-in-surgical-icu-patients-9ad64ef2282f36e8Pharma Surgeen2026-06-29T00:00:00.000ZNCT07672509: Multimodal Sleep Promotion in Surgical ICU Patientshttps://www.pharmaradar360.com/article/nct07669103-bone-cancer-surgery-prospective-database-95d2994ec51da7cfPharma Surgeen2026-06-29T00:00:00.000ZNCT07669103: Bone Cancer Surgery Prospective Databasehttps://www.pharmaradar360.com/article/nct07662187-endometrial-cavity-after-conservative-management-of-pas-patients-by-ae02aebc6ff353e4Pharma Surgeen2026-06-29T00:00:00.000ZNCT07662187: Endometrial Cavity After Conservative Management of PAS Patients by Hysteroscopyhttps://www.pharmaradar360.com/article/nct07634471-a-clinical-trial-of-mk-1045-and-rituximab-in-people-with-follicular-c9ebc913fe2ae21cPharma Surgeen2026-06-29T00:00:00.000ZNCT07634471: A Clinical Trial of MK-1045 and Rituximab in People With Follicular Lymphoma (MK-1045-007)https://www.pharmaradar360.com/article/nct07617636-observational-study-that-will-analyse-the-spread-and-stratification-00a153da59620552Pharma Surgeen2026-06-29T00:00:00.000ZNCT07617636: Observational Study That Will Analyse the Spread and Stratification of Lung Cancer Risk Using Artificial Intelligencehttps://www.pharmaradar360.com/article/nct07610369-the-efficacy-of-psilocybin-therapy-for-depression-in-parkinson-s-dis-b7c97513c065f0a3Pharma Surgeen2026-06-29T00:00:00.000ZNCT07610369: The Efficacy of Psilocybin Therapy for Depression in Parkinson's Diseasehttps://www.pharmaradar360.com/article/nct07569029-a-trial-to-evaluate-the-safety-and-tolerability-of-dv700p-rna-and-dv-1d6a8b9bdadbb10dPharma Surgeen2026-06-29T00:00:00.000ZNCT07569029: A Trial to Evaluate the Safety and Tolerability of DV700P-RNA and DV701B1.1-RNA Immunization in Combination With Antiretroviral Analytical Treatment Interruption (ATI) in People Living With HIV for Elicitation of V3-glycan Antibodieshttps://www.pharmaradar360.com/article/nct07566494-escalating-doses-of-vas-101-in-subjects-with-stable-sickle-cell-dise-89e71199b72a100fPharma Surgeen2026-06-29T00:00:00.000ZNCT07566494: Escalating Doses of VAS-101 in Subjects With Stable Sickle Cell Diseasehttps://www.pharmaradar360.com/article/nct07529626-association-between-chronic-psychological-stress-and-disease-course-f8f4ebcbbfb7d973Pharma Surgeen2026-06-29T00:00:00.000ZNCT07529626: Association Between Chronic Psychological Stress and Disease Course Outcomes in Pancreatic Cancerhttps://www.pharmaradar360.com/article/nct07508761-ipg7236-combined-with-toripalimab-in-participants-with-advanced-soli-feea95f743eaed72Pharma Surgeen2026-06-29T00:00:00.000ZNCT07508761: IPG7236 Combined With Toripalimab in Participants With Advanced Solid Tumorshttps://www.pharmaradar360.com/article/nct07388537-evaluation-of-the-clinical-spectrum-of-diabetes-and-obesity-in-youth-3033397525ec41f9Pharma Surgeen2026-06-29T00:00:00.000ZNCT07388537: Evaluation of the Clinical Spectrum of Diabetes and Obesity in Youth and Adultshttps://www.pharmaradar360.com/article/nct07318324-phase-ib-study-of-avutometinib-defactinib-and-everolimus-in-ras-path-d77d9fd9ca48e2e2Pharma Surgeen2026-06-29T00:00:00.000ZNCT07318324: Phase Ib Study of Avutometinib, Defactinib, and Everolimus in RAS Pathway Mutant Endometrial Cancerhttps://www.pharmaradar360.com/article/nct07318064-ultra-processed-food-consumption-and-health-pilot-study-b78014ede62909d2Pharma Surgeen2026-06-29T00:00:00.000ZNCT07318064: Ultra-processed Food Consumption and Health Pilot Studyhttps://www.pharmaradar360.com/article/nct07233070-hrs-7450-injection-phase-ii-clinical-trial-for-acute-ischemic-stroke-0c2ceda8bb22478cPharma Surgeen2026-06-29T00:00:00.000ZNCT07233070: HRS-7450 Injection Phase II Clinical Trial for Acute Ischemic Stroke.https://www.pharmaradar360.com/article/nct07155707-phase-ii-engagement-and-clinical-impact-of-the-teleo-virtual-therapy-476f22feb8bbfd2ePharma Surgeen2026-06-29T00:00:00.000ZNCT07155707: Phase II: Engagement and Clinical Impact of the Teleo Virtual Therapy Platform in Clinical Settingshttps://www.pharmaradar360.com/article/nct07152821-botensilimab-balstilimab-vs-best-supportive-care-as-therapy-in-chemo-9406fe9c5552aae2Pharma Surgeen2026-06-29T00:00:00.000ZNCT07152821: Botensilimab + Balstilimab vs Best Supportive Care as Therapy in Chemo-refractory, Unresectable, Colorectal Adenocarcinomahttps://www.pharmaradar360.com/article/nct07007065-study-to-assess-the-injection-burden-adverse-events-change-in-diseas-9393b1bd35535031Pharma Surgeen2026-06-29T00:00:00.000ZNCT07007065: Study to Assess the Injection Burden, Adverse Events, Change in Disease Activity, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD)https://www.pharmaradar360.com/article/nct06968845-a-phase-2-study-of-lti-03-in-patients-with-idiopathic-pulmonary-fibr-34003fd2d736b5bePharma Surgeen2026-06-29T00:00:00.000ZNCT06968845: A Phase 2 Study of LTI-03 in Patients With Idiopathic Pulmonary Fibrosishttps://www.pharmaradar360.com/article/nct06819644-optimisation-of-high-flow-oxygen-therapy-settings-during-hypoxaemic-33ed0600dc53b478Pharma Surgeen2026-06-29T00:00:00.000ZNCT06819644: Optimisation of High Flow Oxygen Therapy Settings During Hypoxaemic Respiratory Distress Based on Non-contact Measurement of Lung Volumes by Depth Camerahttps://www.pharmaradar360.com/article/nct06680466-a-phase-ii-study-to-evaluate-the-efficacy-and-safety-of-yzj-4729-in-bb9d4c7ff0dc9185Pharma Surgeen2026-06-29T00:00:00.000ZNCT06680466: A Phase Ⅱ Study to Evaluate the Efficacy and Safety of YZJ-4729 in Patients With Moderate to Severe Acute Pain After Abdominal Surgeryhttps://www.pharmaradar360.com/article/nct06619587-a-study-to-evaluate-safety-pharmacokinetics-and-activity-of-gdc-7035-31c0e9a9b3d7a2cfPharma Surgeen2026-06-29T00:00:00.000ZNCT06619587: A Study to Evaluate Safety, Pharmacokinetics, and Activity of GDC-7035 as a Single Agent and in Combination in Patients With Advanced Solid Tumorshttps://www.pharmaradar360.com/article/nct06583486-a-study-on-the-efficacy-and-safety-of-repeated-treatments-with-recom-91936a09c1716d89Pharma Surgeen2026-06-29T00:00:00.000ZNCT06583486: A Study on the Efficacy and Safety of Repeated Treatments With Recombinant Botulinum Toxin Type A for Injection in the Treatment of Moderate to Severe Glabellar Lineshttps://www.pharmaradar360.com/article/nct06487481-study-of-preoperative-radiation-therapy-in-participants-with-resecta-fc044139700317d0Pharma Surgeen2026-06-29T00:00:00.000ZNCT06487481: Study of Preoperative Radiation Therapy in Participants With Resectable Recurrent Abdominal Adrenocortical Carcinomahttps://www.pharmaradar360.com/article/nct06349460-trial-to-optimize-just-in-time-adaptive-intervention-for-binge-eatin-601b3c9b888f0d06Pharma Surgeen2026-06-29T00:00:00.000ZNCT06349460: Trial to Optimize Just-in-Time Adaptive Intervention for Binge Eating & Weight-related Behaviorshttps://www.pharmaradar360.com/article/nct06281119-clinical-study-to-evaluate-siipl-qhpv-vaccine-cervavac-in-women-livi-260220458ac46db9Pharma Surgeen2026-06-29T00:00:00.000ZNCT06281119: Clinical Study to Evaluate SIIPL qHPV Vaccine (CERVAVAC®) in Women Living With HIV Aged 15-25 Yearshttps://www.pharmaradar360.com/article/nct06031441-a-study-to-evaluate-the-safety-pharmacokinetics-and-activity-of-ro75-09812e160b222c6ePharma Surgeen2026-06-29T00:00:00.000ZNCT06031441: A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7566802 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumorshttps://www.pharmaradar360.com/article/nct05950464-testing-different-amounts-of-the-combination-of-drugs-m1774-and-zen-6e4b8a9b14ee611bPharma Surgeen2026-06-29T00:00:00.000ZNCT05950464: Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancerhttps://www.pharmaradar360.com/article/nct05934487-proactive-hf-2-trial-heart-failure-nyha-class-ii-and-iii-a4a004bdd31234b9Pharma Surgeen2026-06-29T00:00:00.000ZNCT05934487: PROACTIVE-HF-2 Trial Heart Failure NYHA Class II and IIIhttps://www.pharmaradar360.com/article/nct05806437-patient-blood-management-in-the-approach-to-prosthetic-surgery-pbm-l-4fcdb96021aba1c1Pharma Surgeen2026-06-29T00:00:00.000ZNCT05806437: Patient Blood Management in the Approach to Prosthetic Surgery [PBM(L4178)]https://www.pharmaradar360.com/article/nct05698199-study-to-evaluate-the-safety-tolerability-immunogenicity-and-prelimi-1b600b710da2997fPharma Surgeen2026-06-29T00:00:00.000ZNCT05698199: Study to Evaluate the Safety, Tolerability, Immunogenicity and Preliminary Efficacy of ITI-1001 In Patients With Newly Diagnosed Glioblastoma (GBM)https://www.pharmaradar360.com/article/nct05354505-fetal-endoscopic-tracheal-occlusion-feto-trial-for-congenital-diaphr-8934bede4774ace6Pharma Surgeen2026-06-29T00:00:00.000ZNCT05354505: Fetal Endoscopic Tracheal Occlusion (FETO) Trial for Congenital Diaphragmatic Hernia (CDH)https://www.pharmaradar360.com/article/nct05110989-a-multicenter-patient-registry-on-outcomes-from-cryoanalgesia-of-the-2ab206e9770c2062Pharma Surgeen2026-06-29T00:00:00.000ZNCT05110989: A Multicenter Patient Registry on Outcomes From Cryoanalgesia of the Intercostal Nerveshttps://www.pharmaradar360.com/article/nct04566432-therapeutic-resistance-and-clonal-evolution-assessed-with-liquid-bio-59b165b7f9956012Pharma Surgeen2026-06-29T00:00:00.000ZNCT04566432: Therapeutic ResistAnce and Clonal Evolution Assessed With Liquid Biopsy in ICIs Treated NSCLC Patientshttps://www.pharmaradar360.com/article/nct04555577-phase-i-trial-of-dna-pk-inhibitor-peposertib-in-combination-with-rad-c943a465bec68a2ePharma Surgeen2026-06-29T00:00:00.000ZNCT04555577: Phase I Trial of DNA-PK Inhibitor (PEPOSERTIB ) in Combination With Radiation and Adjuvant Temozolomide in Newly Diagnosed MGMT Unmethylated and Recurrent Glioblastomahttps://www.pharmaradar360.com/article/nct02603081-study-to-evaluate-spi-1005-in-adults-with-meniere-s-disease-71bca2529e7a09f6Pharma Surgeen2026-06-29T00:00:00.000ZNCT02603081: Study to Evaluate SPI-1005 in Adults With Meniere's Diseasehttps://www.pharmaradar360.com/article/nct00378924-cardiology-biobank-registry-966ff9972effd80bPharma Surgeen2026-06-29T00:00:00.000ZNCT00378924: Cardiology Biobank Registryhttps://www.pharmaradar360.com/article/can-t-japan-cultivate-top-tier-biotech-companies-f3eefc53297fa21bPharma Surgeen2026-06-28T23:50:16.000ZCan't Japan Cultivate Top-Tier Biotech Companies?https://www.pharmaradar360.com/article/gc-wellbeing-clinches-korea-rights-to-raziel-fat-shot-as-us-phase-3-nears-chosun-29025734be781ab7Pharma Surgeen2026-06-28T23:26:00.000ZGC Wellbeing clinches Korea rights to Raziel fat-shot as US phase 3 nears - CHOSUNBIZhttps://www.pharmaradar360.com/article/gc-green-cross-wellbeing-introduces-fat-dissolving-injectable-ahead-of-u-s-phase-c21612dda2254408Pharma Surgeen2026-06-28T23:19:04.000ZGC Green Cross Wellbeing Introduces Fat-Dissolving Injectable Ahead of U.S. Phase 3 Clinical Trialshttps://www.pharmaradar360.com/article/informe-country-by-country-publico-grupo-norbel-fy25-ef45a5ff0845c3abPharma Surgeen2026-06-28T22:00:00.000ZInforme Country by Country Público_Grupo Norbel FY25https://www.pharmaradar360.com/article/otro-informacion-relevante-c87ba61d8c8d81faPharma Surgeen2026-06-28T22:00:00.000ZOtro información relevantehttps://www.pharmaradar360.com/article/fda-approves-viridian-s-thyroid-eye-disease-drug-competitor-to-a-blockbuster-amg-6dc8874b1c913a3bPharma Surgeen2026-06-28T21:03:09.000ZFDA Approves Viridian’s Thyroid Eye Disease Drug, Competitor to a Blockbuster Amgen Medhttps://www.pharmaradar360.com/article/bill-aims-to-extend-cybersecurity-review-of-made-in-china-medical-devices-24a68aac26f5b553Pharma Surgeen2026-06-28T20:39:29.000ZBill Aims to Extend Cybersecurity Review of Made-in-China Medical Deviceshttps://www.pharmaradar360.com/article/sls-stock-kicks-off-week-in-green-ceo-flags-role-in-eu-biotech-policy-talks-that-85917f0651d26f85Pharma Surgeen2026-06-28T20:37:00.000ZSLS Stock Kicks Off Week In Green: CEO Flags Role In EU Biotech Policy Talks That Could Impact Drug Approvalshttps://www.pharmaradar360.com/article/bridgebio-announces-publication-in-the-new-england-journal-of-medicine-of-phase-a0cdaa806cd779d1Pharma Surgeen2026-06-28T20:17:55.000ZBridgeBio Announces Publication in the New England Journal of Medicine of Phase 3 PROPEL 3 Trial of Oral Infigratinib in Children Living with Achondroplasiahttps://www.pharmaradar360.com/article/fda-recalls-heart-and-blood-pressure-drugs-over-safety-concerns-7515d22b6c19785aPharma Surgeen2026-06-28T20:13:01.000ZFDA recalls heart and blood pressure drugs over safety concernshttps://www.pharmaradar360.com/article/bridgebio-pharma-announces-nejm-publication-and-iccbh-presentation-of-positive-p-8572bdb209fb0711Pharma Surgeen2026-06-28T20:10:00.000ZBridgeBio Pharma Announces NEJM Publication and ICCBH Presentation of Positive Phase 3 PROPEL 3 Data for Oral Infigratinib in Achondroplasiahttps://www.pharmaradar360.com/article/bridgebio-s-achondroplasia-drug-posts-nejm-phase-3-data-9feea786f9fb44aaPharma Surgeen2026-06-28T20:00:00.000ZBridgeBio's achondroplasia drug posts NEJM Phase 3 data